Načítá se...
Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations
Despite the established efficacy of sorafenib in advanced hepatocellular carcinoma (HCC), a significant number of sorafenib-treated patients experience disease progression. Current guidelines recommend either best supportive care or clinical trial enrollment for this population. As such, there remai...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3808569/ https://ncbi.nlm.nih.gov/pubmed/24179481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X13498540 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|